Advertisement

Topics

NewGene Limited Company Profile

20:50 EST 11th December 2018 | BioPortfolio

The demand for testing individuals for genetic disorders or cancers that have arisen from acquired genetic variations is growing year on year.  This is being driven by advances in medical genetics where more disorders are being characterised as having causative genetic variations, coupled with the growth in personalised medicine which demands the determination of a patient’s biological characteristics in order to select the most effective therapy regime.

Molecular genetic diagnostics, has been established as a discipline for over three decades, however the underlying technology that is used to deliver tests is still based on a technique developed in 1977 which is both costly and time consuming.
Established through a partnership between the Newcastle Hospitals NHS Foundation Trust and Newcastle University and staffed by renowned experts from each organisation, NewGene is the pioneer in developing, validating and delivering molecular diagnostics using the latest next generation sequencing and genotyping technologies.

Technologies
The latest high throughput DNA sequencing technologies such as the Roche 454 GS-FLX  and Sequenom MALDI-TOF offer significant benefits to molecular diagnostics in terms of a high quality, fast turnaround and lower costs as compared to current established technologies. Whilst these benefits have been realised in the field of genomic research, until recently there has been very little application in molecular diagnostics.

By deploying these technology platforms, NewGene has the capability to handle large volumes of tests ensuring our clients benefit from the economies of scale through competitive pricing and fast turnarounds.
Created in 2008, NewGene has already developed a range of tests for clinically significant inherited disorders and stratified medicine diagnostics for somatic mutations in cancers, delivering services to several UK National Health Service Trusts and overseas healthcare providers.  NewGene’s clients are benefiting from a high quality, rapid turnaround service that can be accessed at low cost.
Integrated service provision

With a background in UK NHS molecular genetics, NewGene’s core team understands that healthcare providers need a reliable service that delivers high quality results on time. In addition NewGene understands that providers can have different needs on the basis of their current service and in house expertise. NewGene routinely works with clients to understand their needs in order to offer an optimal service.

Broad portfolio of tests.
Whilst NewGene has a portfolio of important tests that are established on the new technologies and a pipeline of new tests undergoing development, we recognise that healthcare providers need access to a broad range of tests covering a range of disorders. NewGene has partnered with three UK NHS Regional Genetic Laboratories who can offer tests for over 100 inherited disorders. This means that clients can access a broad range of services through NewGene.

In addition to molecular diagnostics NewGene also offers a fast turnaround and cost effective sequencing and genotyping service for researchers.

NewGene’s expanding portfolio of tests includes the following:-

  • Hereditary cancers such as breast cancer, colon cancer and various haemato-oncology disorders.
  • Common and rare inherited disorders and syndromes.
  • Stratified medicine tests including KRAS, BRAF and EGFR.

Location

International Centre for Life
Newcastle upon Tyne
NE1 4EP
GB

Contact

Phone: +44 (0)191 242 1923
Email: info@newgene.org.uk


News Articles [32 Associated News Articles listed on BioPortfolio]

Quotient Limited Announces Details of Investor Day

JERSEY, Channel Islands, July 16, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced details of its investor day held at the NASDAQ he...

Quotient Limited to Host Investor Day on July 16, 2018

JERSEY, Channel Islands, June 18, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that it will host an Investor Day on Monday, July ...

Quotient Limited Announces Initial MosaiQ™ SDS Verification and Validation Data

JERSEY, Channel Islands, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), today reported positive Verification and Validation...

Quotient Limited to Participate in the Jefferies 2018 London Healthcare Conference

JERSEY, Channel Islands, Oct. 31, 2018 (GLOBE NEWSWIRE) -- Quotient (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that the Company's Chief Financial Officer, Chris Lindop,...

Quotient Limited Announces Pricing of Underwritten Offering of Ordinary Shares

JERSEY, Channel Islands, Dec. 06, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT) (the Company), a commercial-stage diagnostics company, today announced the pricing of its previously annou...

Quotient Limited Announces Completion of Senior Secured Notes Offering

JERSEY, Channel Islands, July 02, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), has completed the offering of up to $120.0 million ...

Quotient Limited Announces Proposed Underwritten Offering of Ordinary Shares

JERSEY, Channel Islands, Dec. 06, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT) (the Company), a commercial-stage diagnostics company, today announced the Company intends to commence an ...

Quotient Limited to Participate in the 2018 Cantor Fitzgerald Global Healthcare Conference

JERSEY, Channel Islands, Sept. 26, 2018 (GLOBE NEWSWIRE) -- Quotient (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that the Company's Chairman and Chief Executive Officer, ...

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [86 Associated Companies listed on BioPortfolio]

NewGene Limited

The demand for testing individuals for genetic disorders or cancers that have arisen from acquired genetic variations is growing year on year.  This is being driven by advances in medical genet...

Microsulis Medical Limited

Founded in 1997, Microsulis Medical Limited is a UK-based medical device company that exploits specialist intellectual property in medical microwave design to create therapeutic d...

Immunocore Limited

Immunocore Limited is developing innovative biological therapeutics to treat a range of cancers, chronic viral infections and diabetes. Immunocore is a privately owned biotechnology company located ...

SIEMENS CANADA LIMITED

VASUDHA PHARMA CHEM LIMITED

VASUDHA PHARMA CHEM LIMITED (VPCL) is a Company promoted by a team of accomplished technocrats for Bulk Drug industry with a total capital of Rupees 153 million ( US $ 5Million).All the promoters of V...

More Information about "NewGene Limited" on BioPortfolio

We have published hundreds of NewGene Limited news stories on BioPortfolio along with dozens of NewGene Limited Clinical Trials and PubMed Articles about NewGene Limited for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of NewGene Limited Companies in our database. You can also find out about relevant NewGene Limited Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biological Therapy
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...


Corporate Database Quicklinks



Searches Linking to this Company Record